-
Product Insights
NewMesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely,...
-
Product Insights
NewChronic Urticaria Or Hives – Drugs In Development, 2024
Empower your strategies with our Chronic Urticaria Or Hives – Drugs In Development, 2024 report and make more profitable business decisions. Chronic urticaria, also known as hives, are outbreaks of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors...
-
Product Insights
NewMesenchymal Tumor – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors are tumors developing from mesenchymal tissues. These tissues are made of cells including fibroblasts, nerve cells, blood vessel cells, muscle cells, and others. Benign soft tissue tumors are common in humans, but cancerous mesenchymal tumors are rare. Many tumors can originate from various cells, and the treatment mainly depends on the tumor's type, severity, and aggressiveness. These are soft tissue...
-
Product Insights
NewHigh-Grade Glioma – Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
-
Sector Analysis
Asia Pacific (APAC) Renewable Energy Policy Handbook, 2024 Update
Asia Pacific (APAC) Renewable Energy Policy Report Overview All Asia Pacific (APAC) countries covered in this report have set targets for renewable energy deployment and generation. A few countries have capacity targets, and a few have generation targets. In the APAC region, feed-in tariff (FiT) has been predominantly the most popular form of incentive utilized to promote renewable power installations. However, competitive bidding or auctions have also gained popularity in the APAC countries to promote renewable energy, especially solar PV,...
-
Sector Analysis
Singapore Telecom Operators Country Intelligence Report
Singapore Telecom Services Market Overview The total telecom and pay-TV service revenue in Singapore, when valued in local currency, is expected to increase at a CAGR of 0.3% during 2023-2028, primarily supported by fixed broadband and mobile data segments. However, when valued in the US dollars, the revenue seems to decline at a CAGR of 0.2% during the same period, due to the strengthening of the US dollar against the local currency. Singapore Telecom Services Market Outlook, 2023 – 2028...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-451 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BLU-451 in Non-Small Cell Lung Cancer Drug Details: BLU-451 (LNG-451) under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bittera in Prader-Willi Syndrome (PWS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bittera in Prader-Willi Syndrome (PWS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bittera in Prader-Willi Syndrome (PWS) Drug Details: Bittera is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elenestinib in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elenestinib in Systemic Mastocytosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elenestinib in Systemic Mastocytosis Drug Details: BLU-263 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NIM-1324 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NIM-1324 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NIM-1324 in Rheumatoid ArthritisDrug Details:NIM-1324 is under development for the treatment of rheumatoid...